4
Changes in Ownership
Kalaris Therapeutics, Inc. Filed Acc 0001209191-23-043120
Chief Accounting Officer sold 684 shares at an average $3.45 ($2,363)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Hagen Brett R · Chief Accounting Officer
Table I: Non-derivative
2 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2023-07-19 | Sale : show line 1 in the form 10b5-1 | −342 | $3.56 | $1,218 | 129,170 | D |
| 2023-07-20 | Sale : show line 2 in the form 10b5-1 | −342 | $3.35 | $1,145 | 128,828 | D |
| Open-market sales · 684 sh · avg $3.45 · $2,363 | ||||||
Loading xslF345X05/doc4.xml…